January 14, 2014

In this article, Jenner & Block Partner Erin R. Schrantz examines the challenges for U.S. companies participating in joint ventures with Chinese state-owned or controlled enterprises, in maintaining compliance with the U.S. Foreign Corrupt Practices Act as well as Chinese anticorruption laws.  Noting that, “Whether Big Pharma, a big bank or a mid-size manufacturer, U.S. companies in China need robust compliance measures to address the growing dual regulatory pressures,” Erin suggests several possible approaches to strengthening the anticorruption measures in such joint ventures and mitigating the risk of enforcement actions, concluding that “the only effective path forward is a collaborative one.”